Stella Jaeckle
Medical Student, 2023-Present
Stella Jaeckle is a medical student intern who has contributed to data visualization and translational science correlatives for leukemia clinical trials since joining the lab in 2023. She recently graduated from St. Olaf College with a BA in Chemistry and Spanish. She is currently a medical student at the Medical College of Wisconsin working towards a MD/MS dual degree in clinical and translational science in pursuit of a career as an oncology physician-scientist. She has generated figures for various national meetings reporting clinical trial results. During her time in person in the lab, she helped coordinate the correlative science initiatives for a leukemia trial of inotuzumab ozogamicin and venetoclax to explore mechanisms of resistance to this combination treatment regimen. She looks forward to continuing to work virtually in the lab contributing to the analysis, visualization, and presentation of correlative and clinical trial results. Outside of the lab, she enjoys traveling, water skiing, singing, and playing tennis. She can be contacted at Stella_Jaeckle@dfci.harvard.edu.Manuscript(s):
Marlise R. Luskin, Mark A. Murakami, Julia Keating, Yael Flamand, Eric S. Winer, Jacqueline S. Garcia, Maximilian Stahl, Richard M. Stone, Martha Wadleigh, Stella L. Jaeckle, Ella Hagopian, David M. Weinstock, Jessica Liegel, Malgorzata McMasters, Eunice S. Wang, Wendy Stock, Daniel J. DeAngelo. Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia. Blood. 2025;145(6):577-589. doi: https://doi.org/10.1182/blood.2024025800
Published Abstract(s):
Stella L. Jaeckle, Emma M. Smith, Jeremy Ryan, Chase M. Weizer, Matthew A. Booker, Ashreen Williams, Michael Y. Tolstorukov, Daniel J. DeAngelo, Marlise R. Luskin, Anthony Letai, Mark A. Murakami. Molecular and functional determinants of response to venetoclax and inotuzumab ozogamicin in CD22-positive ALL [oral presentation abstract]. Blood. 2025;146(Supplement 1):329. doi: https://doi.org/10.1182/blood-2025-329
Marlise R. Luskin, Julia Keating, Benjamin Frost, Yael Flamand, Jacqueline S. Garcia, Richard M. Stone, Rebecca Leonard, Stella L. Jaeckle, Chase M. Weizer, Jessica Lee, Ilene Galinsky, Jeremy Ryan, Evan C. Chen, Eric S. Winer, Anthony Letai, Mark A. Murakami, Daniel J. DeAngelo. Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a Phase I trial [oral presentation abstract]. Blood. 2025;146(Supplement 1):645. doi: https://doi.org/10.1182/blood-2025-645
Marlise R. Luskin, Julia Keating, Eunice S. Wang, Malgorzata McMasters, Eric S. Winer, Maximilian Stahl, Yael Flamand, Hunter Smith, Stella L. Jaeckle, Chase M. Weizer, Joseph D. Fleming, Caner Saygin, Wendy Stock, Daniel J. DeAngelo, Mark A. Murakami. A Phase I study of asciminib in combination with dasatinib, prednisone, and blinatumomab for Ph-positive acute leukemia in adults [oral presentation abstract]. J Clin Oncol. 2025;43(Supplement 16):6509. doi: https://doi.org/10.1200/JCO.2025.43.16_suppl.6509
Chase M. Weizer, Rachel A. Kran, Evan Ales, Stella L. Jaeckle, Julia H. Keating, Marlise R. Luskin, Robert Sackstein, Mark A. Murakami. E-selectin binding is enriched within B-cell acute lymphoblastic leukemia compared to healthy lymphoid precursors [poster abstract]. Cancer Research. 2025;85(8 Supplement 1):5145. doi: https://doi.org/10.1158/1538-7445.AM2025-5145